Tom 14, Nr 5 (2017)
Zaburzenia rytmu serca
Opublikowany online: 2018-03-06
Wyświetlenia strony
626
Wyświetlenia/pobrania artykułu
4502
Postępowanie w migotaniu przedsionków u pacjentów w podeszłym wieku
Choroby Serca i Naczyń 2017;14(5):248-257.
Streszczenie
Migotanie przedsionków jest jednym z najczęściej występujących zaburzeń rytmu serca. Stanowi niezależny czynnik ryzyka zgonu, jak i podstawę rozwoju i progresji innych schorzeń sercowo – naczyniowych. Ponad to pogarsza jakość życia, zarówno jako choroba zasadnicza, jak i ze względu na powikłania, do których prowadzi.
Częstość występowania migotania przedsionków wzrasta z wiekiem, co jest związane zarówno ze zmianami, jakie zachodzą w budowie serca, m.in. z włóknieniem oraz stłuszczeniem, jak i z częstszym występowaniem schorzeń będących podłożem dla wystąpienia arytmii, tj. wady zastawkowe czy niewydolność serca.
Pomimo tego, iż osoby w wieku podeszłym stanowią najliczniejszą i najbardziej narażoną na powikłania grupę chorych z migotaniem przedsionków, ich leczenie często nie jest optymalne. W wielu sytuacjach próbuje się forsować uzyskanie i utrzymanie rytmu zatokowego narażając pacjentów na procedury inwazyjne, czy farmakoterapię, które w ich przypadku mają ograniczoną skuteczność, z drugiej strony, z obawy przed powikłaniami krwotocznymi, nie włącza się leczenia przeciwzakrzepowego, mającego faktyczne znaczenie dla życia i sprawności chorych.
Słowa kluczowe: migotanie przedsionkówpacjenci w wieku podeszłymleczenie przeciwzakrzepowe
Referencje
- Antonio B, Gianni T, Elena F, et al. Emergency Department Readmission in Elderly Patients After Acute Rhythm or Rate Control Treatment for Atrial Fibrillation. J Atr Fibrillation. 2016; 9(2): 1387.
- Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Kardiol Pol. 2016; 74(12): 1359–1469.
- Lin YK, Chen YA, Lee TI, et al. Aging Modulates the Substrate and Triggers Remodeling in Atrial Fibrillation. Circ J. 2017 [Epub ahead of print].
- Gullón A, Formiga F, Camafort M, et al. NONAVASC study group. Vascular Risk Group of the Spanish Society of Internal Medicine. Baseline functional status as the strongest predictor of in-hospital mortality in elderly patients with non-valvular atrial fibrillation: Results of the NONAVASC registry. Eur J Intern Med. 2018; 47: 69–74.
- Della Rocca DG, Santini L, Forleo GB, et al. Novel perspectives on arrhythmia-induced cardiomyopathy: pathophysiology, clinical manifestations and an update on invasive management strategies. Cardiol Rev. 2015; 23(3): 135–141.
- Tanaka R, Spinale FG, Crawford FA, et al. Effect of chronic supraventricular tachycardia on left ventricular function and structure in newborn pigs. J Am Coll Cardiol. 1992; 20(7): 1650–1660.
- Hollingsworth KG, Blamire AM, Keavney BD, et al. Left ventricular torsion, energetics, and diastolic function in normal human aging. Am J Physiol Heart Circ Physiol. 2012; 302(4): H885–H892.
- Ponikowski P, Voors AA, Anker SD, et al. Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37(27): 2129–2200.
- Ling LH, Kistler PM, Kalman JM, et al. Comorbidity of atrial fibrillation and heart failure. Nat Rev Cardiol. 2016; 13(3): 131–147.
- Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015; 17(10): 1467–1507.
- Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology and rationale for therapy. Am J Cardiol. 2013; 167: 1217–1225.
- Cullington D, Goode KM, Zhang J, et al. Is heart rate important for patients with heart failure in atrial fibrillation? JACC Heart Fail. 2014; 2(3): 213–220.
- Abreu A, Oliveira M, Silva Cunha P, et al. BETTER-HF investigators. Does permanent atrial fibrillation modify response to cardiac resynchronization therapy in heart failure patients? Rev Port Cardiol. 2017; 36(10): 687–694.
- Hügl B, Bruns HJ, Unterberg-Buchwald C, et al. Atrial fibrillation burden during the post-implant period after crt using device-based diagnostics. J Cardiovasc Electrophysiol. 2006; 17(8): 813–817.
- Birnie D, Hudnall H, Lemke B, et al. Continuous optimization of cardiac resynchronization therapy reduces atrial fibrillation in heart failure patients: Results of the Adaptive Cardiac Resynchronization Therapy Trial. Heart Rhythm. 2017; 14(12): 1820–1825.
- Sethi NJ, Feinberg J, Nielsen EE, et al. The effects of rhythm control strategies versus rate control strategies for atrial fibrillation and atrial flutter: A systematic review with meta-analysis and Trial Sequential Analysis. PLoS One. 2017; 12(10): e0186856.
- Kis Z, Noten AMe, Martirosyan M, et al. Comparison of long-term outcome between patients aged < 65 years vs. ≥ 65 years after atrial fibrillation ablation. J Geriatr Cardiol. 2017; 14(9): 569–574.
- Schnabel RB, Yin X, Gona P, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet. 2015; 386(9989): 154–162.
- Karam BS, Chavez-Moreno A, Koh W, et al. Oxidative stress and inflammation as central mediators of atrial fibrillation in obesity and diabetes. Cardiovasc Diabetol. 2017; 16(1): 120.
- Takahashi K, Sasano T, Sugiyama K, et al. High-fat diet increases vulnerability to atrial arrhythmia by conduction disturbance via miR-27b. J Mol Cell Cardiol. 2016; 90: 38–46.
- Mahajan R, Lau DH, Brooks AG, et al. Electrophysiological, Electroanatomical, and Structural Remodeling of the Atria as Consequences of Sustained Obesity. J Am Coll Cardiol. 2015; 66(1): 1–11.
- Mayyas F, Alzoubi KH, Van Wagoner DR. Impact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone promotes oxidative stress and atrial structural/electrical remodeling. Int J Cardiol. 2013; 168(6): 5135–5142.
- Rayner JJ, Banerjee R, Holloway CJ, et al. The relative contribution of metabolic and structural abnormalities to diastolic dysfunction in obesity. Int J Obes (Lond). 2017 [Epub ahead of print].
- Santos JV, Pereira J, Pinto R, et al. Atrial Fibrillation as an Ischemic Stroke Clinical and Economic Burden Modifier: A 15-Year Nationwide Study. Value Health. 2017; 20(8): 1083–1091.
- Labuz-Roszak B, Pierzchala K, Skrzypek M, et al. Oral anticoagulant and antiplatelet drugs used in prevention of cardiovascular events in elderly people in Poland. BMC Cardiovasc Disord. 2012; 12: 98.
- Connolly S, Pogue J, Hart R, et al. ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006; 367(9526): 1903–1912.
- Poli D, Lip GYh, Antonucci E, et al. Stroke risk stratification in a. J Cardiovasc Electrophysiol. 2011; 22(1): 25–30.
- Boriani G, Proietti M, Laroche C, et al. EORP-AF Long-Term General Registry Investigators. Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry. Europace. 2017.
- Stępińska J, Kremis E, Konopka A, et al. Stroke prevention in atrial fibrillation patients in Poland and other European countries: insights from the GARFIELD-AF registry. Kardiol Pol. 2016; 74(4): 362–371.
- Bai Y, Guo SD, Deng H, et al. Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-regression analysis. Age Ageing. 2018; 47(1): 9–17.
- Kristensen SD, Knuuti J, Saraste A, et al. Authors/Task Force Members. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J. 2014; 35(35): 2383–2431.
- Valgimigli M, Bueno H, Byrne RA, et al. ESC Scientific Document Group, ESC Committee for Practice Guidelines (CPG), ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018; 39(3): 213–260.
- Casu G, Gulizia MM, Molon G, et al. ANMCO/AIAC/SICI-GISE/SIC/SICCH Consensus Document: percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation patients: indications, patient selection, staff skills, organisation, and training. Eur Heart J Suppl. 2017; 19(Suppl D): D333–D353.
- Grönberg T, Nuotio I, Nikkinen M, et al. Arrhythmic complications after electrical cardioversion of acute atrial fibrillation: the FinCV study. Europace. 2013; 15(10): 1432–1435.
- Jaakkola S, Lip GYH, Biancari F, et al. Predicting Unsuccessful Electrical Cardioversion for Acute Atrial Fibrillation (from the AF-CVS Score). Am J Cardiol. 2017; 119(5): 749–752.
